| Generic name | Bendamustine hydrochloride |
| Pronunciation | BEN-da-MUS-teen HYE-droe-KLOR-ide |
| Brand name(s), other common name(s) | Treanda® |
| Drug type | Alkylating agent |
| How the drug is given | Intravenously (IV) |
| Generic name | Bendamustine hydrochloride |
| Pronunciation | BEN-da-MUS-teen HYE-droe-KLOR-ide |
| Brand name(s), other common name(s) | BENDEKATM |
| Drug type | Alkylating agent |
| How the drug is given | Intravenously (IV) |
Indications and Usage
Bendamustine hydrochloride is FDA approved to treat people who have:
- Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.
- Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Side effects needing medical attention
Low blood cell counts, infections, infusion reactions, anaphylaxis, tumor lysis syndrome, skin reactions, other cancers, leaking of bendamustine hydrochloride out of your vein and into your surrounding skin, fever, nausea, and vomiting.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.